ZNTL · ISSUER CIK 1725160
Zentalis Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 2 Zentalis Pharmaceuticals, Inc. insiders reported $15.2M of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Walters Group (10% Owner), with $15.2M.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$15.2MInsider buying
$0.00Insider selling
+$15.2MNet open-market
Oct 1, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 202617:19 | Sep 30, 2026 | ZNTL | Chief Medical Officer | A · Grant | $2.18 | +9,727 | 43,059 | +29% | $21K | ||
| Aug 19, 202618:11 | Aug 14, 2026 | ZNTL | 10% Owner · +2 joint | P · BuyLate 5d | $3.50 | +4,335,000 | 17,844,973 | +32% | +$15.2M | -31.5% | -43.1% |